Docetaxel given after doxorubicin reduces recurrence

January 08, 2008

Adding the drug docetaxel to anthracycline-based chemotherapy slightly improved disease-free survival in breast cancer patients, according to a randomized clinical trial published online January 8 in the Journal of the National Cancer Institute.

Docetaxel has previously been shown to be more effective than doxorubicin (an anthracycline) for treating patients with advanced breast cancer. Therefore, researchers wanted to test it in patients receiving chemotherapy after surgery.

Prudence Francis, M.D., of the Peter MacCallum Cancer Centre in Melbourne, Australia, and colleagues conducted a randomized, controlled phase III trial that compared patients who received doxorubicin-based chemotherapy with and without docetaxel. The trial also examined whether docetaxel should be given after doxorubicin or at the same time. The researchers compared disease-free survival for each treatment.

Overall, patients receiving the docetaxel treatment had an improvement in disease-free survival that was borderline statistically significant. Patients receiving docetaxel after doxorubicin had a five-year disease-free survival rate of 78 percent, compared with 74 percent for those receiving the two drugs at the same time. Patients in the control arm--those who received only doxorubicin-based chemotherapy--had a five-year disease-free survival rate of 73 percent. However, there was no statistically significant difference in overall survival between patients who received docetaxel and those who did not.

"Important differences may be related to doxorubicin and docetaxel scheduling, with sequential, but not concurrent, administration appearing to produce better [disease-free survival] than anthracycline-based adjuvant chemotherapy," the authors write.
-end-
Contact: Prudence Francis, prue.francis@petermac.org, 61-3-9509-2514

Citations: Francis P, Crown J, Di Leo A, Buyse M, Balil A, Andersson M, Nordenskjöld B, Lang I, et al. Adjuvant Chemotherapy With Sequential or Concurrent Anthracycline and Docetaxel: Breast International Group 02 - 98 Randomized Trial. J Natl Cancer Inst 2008; 100:121-133

Note to Reporters:

We have started up an e-mail list to alert reporters when papers are available on the EurekAlert site. If you would be interested on being on this list, please let us know at jncimedia@oxfordjournals.org. The content will continue to be available through EurekAlert's e-mail system and our EurekAlert page.

The Journal of the National Cancer Institute is published by Oxford University Press and is not affiliated with the National Cancer Institute. Attribution to the Journal of the National Cancer Institute is requested in all news coverage. Visit the Journal online at http://jnci.oxfordjournals.org/.

Journal of the National Cancer Institute

Related Breast Cancer Patients Articles from Brightsurf:

Not all patients are offered the same effective breast cancer treatment
Socioeconomic status and race could play a role in treatment decisions, according to new research.

Antioxidant use during chemotherapy risky for breast cancer patients
Breast cancer patients who take the dietary supplements known as antioxidants, as well as iron, vitamin B12, and omega-3 fatty acids, during chemotherapy may be at increased risk of disease recurrence and death, according to new study results appearing in the Journal of Clinical Oncology.

Breast cancer patients to be evaluated for genetic testing
The guidance from the ACMG differs from a consensus guideline issued in February by the American Society of Breast Surgeons, which recommended genetic testing for all newly diagnosed patients with breast cancer.

Cancer tissue-freezing approach may help more breast cancer patients in lower income countries
A new reusable device created by the Johns Hopkins University can help women with breast cancer in lower income countries by using carbon dioxide, a widely available and affordable gas, to power a cancer tissue-freezing probe instead of industry-standard argon.

Genetic testing does not cause undue worry for breast cancer patients
As genetic testing for breast cancer has become more complex, evaluating a panel of multiple genes, it introduces more uncertainty about the results.

Pregnancy possible after chemotherapy for breast cancer patients, but many no longer wish
Chemotherapy is known to have a negative impact on the reproductive potential of young breast cancer patients.

Older breast cancer patients in England less likely to survive
Older women diagnosed with breast cancer in England are less likely to survive their disease than those in Belgium, Poland, Ireland and the Netherlands according to research published today in the British Journal of Cancer.

Three-in-one molecule shows promise in helping certain breast cancer patients
A newly designed three-part molecule could be the one answer patients with a certain form of breast cancer are looking for, scientists report.

Breast cancer patients often mispredict well-being after mastectomy
Women with breast cancer who underwent a mastectomy without breast reconstruction generally underestimated their future quality of life, while those who had immediate reconstruction generally overestimated it.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer Patients News and Breast Cancer Patients Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.